How It Works and Eligibility Requirements
Daraxonrasib has emerged as a significant advancement for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), demonstrating superior survival outcomes compared to standard chemotherapy. According to data published in the New England Journal of Medicine in May 2026, the drug effectively targets RAS gene mutations, which drive cell growth in over 90 percent of pancreatic cancer … Read more